<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883412</url>
  </required_header>
  <id_info>
    <org_study_id>20320</org_study_id>
    <nct_id>NCT03883412</nct_id>
  </id_info>
  <brief_title>Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)</brief_title>
  <acronym>ZQL007</acronym>
  <official_title>Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine whether exercise training alone,
      liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac
      and muscle capillary blood volume, improves vascular function in the larger conduit vessels,
      and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be
      randomized to one of the three groups: exercise training, liraglutide treatment, and exercise
      + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our hypothesis is that sustained activation of the GLP-1 receptor with Liraglutide or
      exercise training will enhance microvascular perfusion, promote angiogenesis, and improve
      microvascular response to insulin in muscle, leading to increased muscle delivery of oxygen
      and nutrients and increased exercise tolerance in subjects with type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular Blood Volume - change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index - change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Dilation - change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Wave Velocity - change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Ischemic Flow Velocity-Change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity-Change from baseline</measure>
    <time_frame>16 weeks</time_frame>
    <description>measured at baseline and 16 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Exercise Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise + Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>16 weeks of treatment</description>
    <arm_group_label>Exercise + Liraglutide</arm_group_label>
    <arm_group_label>Exercise Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>16 weeks of Liraglutide</description>
    <arm_group_label>Exercise + Liraglutide</arm_group_label>
    <arm_group_label>Liraglutide alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-60

          -  A1C â‰¤ 8.5%

          -  Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)

          -  On stable dose of oral hypoglycemic agents &gt;4 months

          -  On stable dose of other medications for &gt;4 months

        Exclusion Criteria:

          -  Taking Insulin

          -  Smoking presently or in the past 6 months

          -  BP &gt;160/90

          -  BMI &gt;35

          -  Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome

          -  History of congestive heart failure, ischemic heart disease, severe pulmonary disease,
             liver or kidney disease.

          -  Any vascular disease such as myocardial infarction, stroke, peripheral vascular
             disease

          -  Presence of an intracardiac or intrapulmonary shunt (we will screen for this by
             auscultation during the physical exam by PI).

          -  Pregnant or breastfeeding.

          -  Known hypersensitivity to perflutren (contained in Definity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenqi Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia, Department of Endocrinoolgy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Hartline, MEd</last_name>
    <phone>434-924-5247</phone>
    <email>lmh9d@virginia.eud</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Jahn, RN, MEd</last_name>
    <phone>434-924-1134</phone>
    <email>las6e@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenqi Liu, MD</last_name>
      <phone>434-243-2603</phone>
      <email>zl3e@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eugene Barrett, MD, PhD</last_name>
      <phone>434-924-1175</phone>
      <email>ejb8x@virginia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011 Jan 4;123(1):87-97. doi: 10.1161/CIRCULATIONAHA.109.881888. Review.</citation>
    <PMID>21200015</PMID>
  </reference>
  <reference>
    <citation>Honig CR, Odoroff CL, Frierson JL. Active and passive capillary control in red muscle at rest and in exercise. Am J Physiol. 1982 Aug;243(2):H196-206.</citation>
    <PMID>7114231</PMID>
  </reference>
  <reference>
    <citation>Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, Liu Z. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009 May;52(5):752-64. doi: 10.1007/s00125-009-1313-z. Epub 2009 Mar 13. Review.</citation>
    <PMID>19283361</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes. 2004 Jun;53(6):1418-23.</citation>
    <PMID>15161743</PMID>
  </reference>
  <reference>
    <citation>Eggleston EM, Jahn LA, Barrett EJ. Hyperinsulinemia rapidly increases human muscle microvascular perfusion but fails to increase muscle insulin clearance: evidence that a saturable process mediates muscle insulin uptake. Diabetes. 2007 Dec;56(12):2958-63. Epub 2007 Aug 24.</citation>
    <PMID>17720897</PMID>
  </reference>
  <reference>
    <citation>Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension. 2010 Feb;55(2):523-30. doi: 10.1161/HYPERTENSIONAHA.109.145409. Epub 2009 Dec 7.</citation>
    <PMID>19996061</PMID>
  </reference>
  <reference>
    <citation>Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. J Clin Endocrinol Metab. 2009 Sep;94(9):3543-9. doi: 10.1210/jc.2009-0027. Epub 2009 Jun 30.</citation>
    <PMID>19567533</PMID>
  </reference>
  <reference>
    <citation>Liu J, Jahn LA, Fowler DE, Barrett EJ, Cao W, Liu Z. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans. J Clin Endocrinol Metab. 2011 Feb;96(2):438-46. doi: 10.1210/jc.2010-1174. Epub 2010 Nov 3.</citation>
    <PMID>21047922</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E123-9.</citation>
    <PMID>12791603</PMID>
  </reference>
  <reference>
    <citation>Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999 Aug;104(4):447-57.</citation>
    <PMID>10449437</PMID>
  </reference>
  <reference>
    <citation>Kim JA, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol. 2005 May;25(5):889-91.</citation>
    <PMID>15863720</PMID>
  </reference>
  <reference>
    <citation>Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006 Apr 18;113(15):1888-904. Review.</citation>
    <PMID>16618833</PMID>
  </reference>
  <reference>
    <citation>Rattigan S, Clark MG, Barrett EJ. Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Diabetes. 1999 Mar;48(3):564-9.</citation>
    <PMID>10078557</PMID>
  </reference>
  <reference>
    <citation>Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes. 2000 Nov;49(11):1904-9.</citation>
    <PMID>11078458</PMID>
  </reference>
  <reference>
    <citation>Clerk LH, Rattigan S, Clark MG. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes. 2002 Apr;51(4):1138-45.</citation>
    <PMID>11916937</PMID>
  </reference>
  <reference>
    <citation>Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG. Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes. 2002 Dec;51(12):3492-8.</citation>
    <PMID>12453905</PMID>
  </reference>
  <reference>
    <citation>Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006 May;55(5):1436-42.</citation>
    <PMID>16644702</PMID>
  </reference>
  <reference>
    <citation>Chai W, Liu J, Jahn LA, Fowler DE, Barrett EJ, Liu Z. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011 Jul;34(7):1634-8. doi: 10.2337/dc10-2345. Epub 2011 May 26.</citation>
    <PMID>21617098</PMID>
  </reference>
  <reference>
    <citation>Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, Montagnani M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H813-22. Epub 2005 Mar 25.</citation>
    <PMID>15792994</PMID>
  </reference>
  <reference>
    <citation>Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res. 2002 Dec;56(3):464-71.</citation>
    <PMID>12445887</PMID>
  </reference>
  <reference>
    <citation>Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2043-8. Epub 2004 Apr 1.</citation>
    <PMID>15059773</PMID>
  </reference>
  <reference>
    <citation>Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-JÃ¤rvinen H, Christin L, Secomb TW, Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987 Aug;80(2):415-24.</citation>
    <PMID>3301899</PMID>
  </reference>
  <reference>
    <citation>Gavin TP, Stallings HW 3rd, Zwetsloot KA, Westerkamp LM, Ryan NA, Moore RA, Pofahl WE, Hickner RC. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. J Appl Physiol (1985). 2005 Jan;98(1):315-21. Epub 2004 Aug 6.</citation>
    <PMID>15298982</PMID>
  </reference>
  <reference>
    <citation>Akerstrom T, Laub L, Vedel K, Brand CL, Pedersen BK, Lindqvist AK, Wojtaszewski JF, Hellsten Y. Increased skeletal muscle capillarization enhances insulin sensitivity. Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1105-16. doi: 10.1152/ajpendo.00020.2014. Epub 2014 Oct 28.</citation>
    <PMID>25352432</PMID>
  </reference>
  <reference>
    <citation>Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006 May;7(5):359-71. Review.</citation>
    <PMID>16633338</PMID>
  </reference>
  <reference>
    <citation>Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007 Oct 26;101(9):948-56. Epub 2007 Sep 6.</citation>
    <PMID>17823371</PMID>
  </reference>
  <reference>
    <citation>Tang K, Breen EC, Gerber HP, Ferrara NM, Wagner PD. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics. 2004 Jun 17;18(1):63-9. Epub 2004 Jun 17.</citation>
    <PMID>15084712</PMID>
  </reference>
  <reference>
    <citation>Bonner JS, Lantier L, Hasenour CM, James FD, Bracy DP, Wasserman DH. Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance. Diabetes. 2013 Feb;62(2):572-80. doi: 10.2337/db12-0354. Epub 2012 Sep 21.</citation>
    <PMID>23002035</PMID>
  </reference>
  <reference>
    <citation>Robbins JL, Jones WS, Duscha BD, Allen JD, Kraus WE, Regensteiner JG, Hiatt WR, Annex BH. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J Appl Physiol (1985). 2011 Jul;111(1):81-6. doi: 10.1152/japplphysiol.00141.2011. Epub 2011 Apr 21.</citation>
    <PMID>21512146</PMID>
  </reference>
  <reference>
    <citation>Lindner JR, Womack L, Barrett EJ, Weltman J, Price W, Harthun NL, Kaul S, Patrie JT. Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc Imaging. 2008 May;1(3):343-50. doi: 10.1016/j.jcmg.2008.04.001.</citation>
    <PMID>19356447</PMID>
  </reference>
  <reference>
    <citation>Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994 Oct;90(4):1866-74.</citation>
    <PMID>7923674</PMID>
  </reference>
  <reference>
    <citation>Brendle DC, Joseph LJ, Corretti MC, Gardner AW, Katzel LI. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol. 2001 Feb 1;87(3):324-9.</citation>
    <PMID>11165969</PMID>
  </reference>
  <reference>
    <citation>Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, GrÃ¶ger M, Fialka-Moser V, Gschwandtner M, Koppensteiner R, Steiner S. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial. Atherosclerosis. 2011 Jul;217(1):240-8. doi: 10.1016/j.atherosclerosis.2011.03.018. Epub 2011 Apr 8.</citation>
    <PMID>21481871</PMID>
  </reference>
  <reference>
    <citation>Januszek R, Mika P, Konik A, Petriczek T, Nowobilski R, NiÅ¼ankowski R. Effect of treadmill training on endothelial function and walking abilities in patients with peripheral arterial disease. J Cardiol. 2014 Aug;64(2):145-51. doi: 10.1016/j.jjcc.2013.12.002. Epub 2014 Jan 14.</citation>
    <PMID>24438856</PMID>
  </reference>
  <reference>
    <citation>Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation. 1987 Nov;76(5):1110-4.</citation>
    <PMID>3499255</PMID>
  </reference>
  <reference>
    <citation>Vincent MA, Clerk LH, Lindner JR, Price WJ, Jahn LA, Leong-Poi H, Barrett EJ. Mixed meal and light exercise each recruit muscle capillaries in healthy humans. Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1191-7.</citation>
    <PMID>16682488</PMID>
  </reference>
  <reference>
    <citation>Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. Microcirculation. 2014 May;21(4):301-14. doi: 10.1111/micc.12117. Review.</citation>
    <PMID>24450403</PMID>
  </reference>
  <reference>
    <citation>Inyard AC, Clerk LH, Vincent MA, Barrett EJ. Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake. Diabetes. 2007 Sep;56(9):2194-200. Epub 2007 Jun 11.</citation>
    <PMID>17563063</PMID>
  </reference>
  <reference>
    <citation>Wheatley CM, Rattigan S, Richards SM, Barrett EJ, Clark MG. Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats. Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E804-9. Epub 2004 Jun 22.</citation>
    <PMID>15213062</PMID>
  </reference>
  <reference>
    <citation>St-Pierre P, Keith LJ, Richards SM, Rattigan S, Keske MA. Microvascular blood flow responses to muscle contraction are not altered by high-fat feeding in rats. Diabetes Obes Metab. 2012 Aug;14(8):753-61. doi: 10.1111/j.1463-1326.2012.01598.x. Epub 2012 Apr 18.</citation>
    <PMID>22429614</PMID>
  </reference>
  <reference>
    <citation>Olfert IM, Howlett RA, Tang K, Dalton ND, Gu Y, Peterson KL, Wagner PD, Breen EC. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice. J Physiol. 2009 Apr 15;587(Pt 8):1755-67. doi: 10.1113/jphysiol.2008.164384. Epub 2009 Feb 23.</citation>
    <PMID>19237429</PMID>
  </reference>
  <reference>
    <citation>Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, Michaels J, Stansby G. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012 Dec;99(12):1630-8. doi: 10.1002/bjs.8895. Epub 2012 Oct 3. Review.</citation>
    <PMID>23034699</PMID>
  </reference>
  <reference>
    <citation>Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MG, Rouwet EV, Spronk S. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg. 2012 Oct;56(4):1132-42. doi: 10.1016/j.jvs.2012.04.046. Review.</citation>
    <PMID>23026425</PMID>
  </reference>
  <reference>
    <citation>Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13. Epub 2006 Feb 17.</citation>
    <PMID>16489128</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Zhenqi Liu, MD</investigator_full_name>
    <investigator_title>Deparment of Medicine, Chief of Div. Endocrinology, University of Virginia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

